PubMed:28401876 JSONTXT

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T10","span":{"begin":773,"end":776},"obj":"CI"},{"id":"T11","span":{"begin":777,"end":780},"obj":"CI"},{"id":"T12","span":{"begin":781,"end":784},"obj":"CI"},{"id":"T13","span":{"begin":660,"end":663},"obj":"CI"},{"id":"T14","span":{"begin":668,"end":671},"obj":"CI"},{"id":"T15","span":{"begin":664,"end":667},"obj":"CI"},{"id":"T16","span":{"begin":987,"end":990},"obj":"CI"},{"id":"T17","span":{"begin":991,"end":994},"obj":"CI"},{"id":"T18","span":{"begin":995,"end":998},"obj":"CI"},{"id":"T19","span":{"begin":1085,"end":1088},"obj":"CI"},{"id":"T2","span":{"begin":13,"end":21},"obj":"CI"},{"id":"T20","span":{"begin":1089,"end":1092},"obj":"CI"},{"id":"T21","span":{"begin":1093,"end":1096},"obj":"CI"},{"id":"T22","span":{"begin":1186,"end":1189},"obj":"CI"},{"id":"T23","span":{"begin":1190,"end":1193},"obj":"CI"},{"id":"T24","span":{"begin":1194,"end":1197},"obj":"CI"},{"id":"T25","span":{"begin":1424,"end":1427},"obj":"CI"},{"id":"T26","span":{"begin":1428,"end":1431},"obj":"CI"},{"id":"T27","span":{"begin":1432,"end":1435},"obj":"CI"},{"id":"T28","span":{"begin":1700,"end":1703},"obj":"CI"},{"id":"T29","span":{"begin":1704,"end":1707},"obj":"CI"},{"id":"T3","span":{"begin":22,"end":32},"obj":"CI"},{"id":"T30","span":{"begin":1708,"end":1711},"obj":"CI"},{"id":"T31","span":{"begin":1796,"end":1799},"obj":"CI"},{"id":"T32","span":{"begin":1800,"end":1803},"obj":"CI"},{"id":"T33","span":{"begin":1804,"end":1807},"obj":"CI"},{"id":"T34","span":{"begin":1846,"end":1849},"obj":"CI"},{"id":"T35","span":{"begin":1850,"end":1853},"obj":"CI"},{"id":"T36","span":{"begin":1854,"end":1857},"obj":"CI"},{"id":"T4","span":{"begin":370,"end":382},"obj":"CI"},{"id":"T5","span":{"begin":383,"end":393},"obj":"CI"},{"id":"T6","span":{"begin":361,"end":369},"obj":"CI"},{"id":"T7","span":{"begin":395,"end":398},"obj":"CI"},{"id":"T8","span":{"begin":399,"end":402},"obj":"CI"},{"id":"T9","span":{"begin":403,"end":406},"obj":"CI"},{"id":"T49","span":{"begin":1907,"end":1910},"obj":"DP"},{"id":"T50","span":{"begin":864,"end":867},"obj":"DP"},{"id":"T51","span":{"begin":500,"end":503},"obj":"DP"},{"id":"T52","span":{"begin":267,"end":270},"obj":"DP"}],"text":"Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.\nBACKGROUND: Simplified dosing regimens are important for patients who face challenges in adhering to HIV-1 therapy. We investigated the safety and virological efficacy of switching to once-daily abacavir/dolutegravir/lamivudine (ABC/DTG/3TC).\nMETHODS: The STRIIVING study was a randomized, open-label, Phase IIIb study in adults with HIV-1 RNA \u003c50 copies/ml on antiretroviral therapy (ART) at enrolment (ClinicalTrials.gov identifier, NCT02105987). Subjects were randomly assigned to switch to ABC/DTG/3TC once daily for 48 weeks (early-switch group) or continue current ART for 24 weeks and then switch to ABC/DTG/3TC (late-switch group). The primary end point was the proportion of subjects with HIV-1 RNA \u003c50 copies/ml at week 24.\nRESULTS: Of 553 subjects enrolled, 275 were randomly assigned to switch immediately to ABC/DTG/3TC and 278 continued on current ART. At week 24, 85% and 88% of subjects who switched to ABC/DTG/3TC or remained on current ART, respectively, were virologically suppressed, indicating that ABC/DTG/3TC was non-inferior (difference in proportion, -3.4%; 95% CI -9.1, 2.4). At week 48, 83% and 92% were virologically suppressed in the early- and late-switch groups, respectively. Adverse events were reported more frequently with ABC/DTG/3TC (66%) than with current ART (47%) by week 24, and in the late-switch group, 60% of subjects reported adverse events post-switch. Pharmacokinetic data supported immediate switch. HIV Treatment Satisfaction Questionnaire scores improved in participants switching to ABC/DTG/3TC versus current ART.\nCONCLUSIONS: Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T10","span":{"begin":987,"end":990},"obj":"CI"},{"id":"T11","span":{"begin":1085,"end":1088},"obj":"CI"},{"id":"T12","span":{"begin":1186,"end":1189},"obj":"CI"},{"id":"T13","span":{"begin":1424,"end":1427},"obj":"CI"},{"id":"T14","span":{"begin":1700,"end":1703},"obj":"CI"},{"id":"T15","span":{"begin":1796,"end":1799},"obj":"CI"},{"id":"T16","span":{"begin":1846,"end":1849},"obj":"CI"},{"id":"T17","span":{"begin":399,"end":402},"obj":"CI"},{"id":"T18","span":{"begin":664,"end":667},"obj":"CI"},{"id":"T19","span":{"begin":777,"end":780},"obj":"CI"},{"id":"T2","span":{"begin":13,"end":21},"obj":"CI"},{"id":"T20","span":{"begin":991,"end":994},"obj":"CI"},{"id":"T21","span":{"begin":1089,"end":1092},"obj":"CI"},{"id":"T22","span":{"begin":1190,"end":1193},"obj":"CI"},{"id":"T23","span":{"begin":1428,"end":1431},"obj":"CI"},{"id":"T24","span":{"begin":1704,"end":1707},"obj":"CI"},{"id":"T25","span":{"begin":1800,"end":1803},"obj":"CI"},{"id":"T26","span":{"begin":1850,"end":1853},"obj":"CI"},{"id":"T27","span":{"begin":403,"end":406},"obj":"CI"},{"id":"T28","span":{"begin":668,"end":671},"obj":"CI"},{"id":"T29","span":{"begin":781,"end":784},"obj":"CI"},{"id":"T3","span":{"begin":361,"end":369},"obj":"CI"},{"id":"T30","span":{"begin":995,"end":998},"obj":"CI"},{"id":"T31","span":{"begin":1093,"end":1096},"obj":"CI"},{"id":"T32","span":{"begin":1194,"end":1197},"obj":"CI"},{"id":"T33","span":{"begin":1432,"end":1435},"obj":"CI"},{"id":"T34","span":{"begin":1708,"end":1711},"obj":"CI"},{"id":"T35","span":{"begin":1804,"end":1807},"obj":"CI"},{"id":"T36","span":{"begin":1854,"end":1857},"obj":"CI"},{"id":"T4","span":{"begin":22,"end":32},"obj":"CI"},{"id":"T44","span":{"begin":864,"end":867},"obj":"DP"},{"id":"T45","span":{"begin":1907,"end":1910},"obj":"DP"},{"id":"T5","span":{"begin":383,"end":393},"obj":"CI"},{"id":"T6","span":{"begin":370,"end":382},"obj":"CI"},{"id":"T7","span":{"begin":395,"end":398},"obj":"CI"},{"id":"T8","span":{"begin":660,"end":663},"obj":"CI"},{"id":"T9","span":{"begin":773,"end":776},"obj":"CI"},{"id":"T46","span":{"begin":267,"end":270},"obj":"DP"},{"id":"T47","span":{"begin":500,"end":503},"obj":"DP"}],"text":"Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.\nBACKGROUND: Simplified dosing regimens are important for patients who face challenges in adhering to HIV-1 therapy. We investigated the safety and virological efficacy of switching to once-daily abacavir/dolutegravir/lamivudine (ABC/DTG/3TC).\nMETHODS: The STRIIVING study was a randomized, open-label, Phase IIIb study in adults with HIV-1 RNA \u003c50 copies/ml on antiretroviral therapy (ART) at enrolment (ClinicalTrials.gov identifier, NCT02105987). Subjects were randomly assigned to switch to ABC/DTG/3TC once daily for 48 weeks (early-switch group) or continue current ART for 24 weeks and then switch to ABC/DTG/3TC (late-switch group). The primary end point was the proportion of subjects with HIV-1 RNA \u003c50 copies/ml at week 24.\nRESULTS: Of 553 subjects enrolled, 275 were randomly assigned to switch immediately to ABC/DTG/3TC and 278 continued on current ART. At week 24, 85% and 88% of subjects who switched to ABC/DTG/3TC or remained on current ART, respectively, were virologically suppressed, indicating that ABC/DTG/3TC was non-inferior (difference in proportion, -3.4%; 95% CI -9.1, 2.4). At week 48, 83% and 92% were virologically suppressed in the early- and late-switch groups, respectively. Adverse events were reported more frequently with ABC/DTG/3TC (66%) than with current ART (47%) by week 24, and in the late-switch group, 60% of subjects reported adverse events post-switch. Pharmacokinetic data supported immediate switch. HIV Treatment Satisfaction Questionnaire scores improved in participants switching to ABC/DTG/3TC versus current ART.\nCONCLUSIONS: Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression."}